Literature DB >> 22121879

Identification and biology of α-secretase.

Valérie Vingtdeux1, Philippe Marambaud1.   

Abstract

'Secretase' is a generic term coined more than 20 years ago to refer to a group of proteases responsible for the cleavage of a vast number of membrane proteins. These endoproteolytic events result in the extracellular or intracellular release of soluble metabolites associated with a broad range of intrinsic physiological functions. α-Secretase refers to the activity targeting the amyloid precursor protein (APP) and generating sAPPα, a soluble extracellular fragment potentially associated with neurotrophic and neuroprotective functions. Several proteases from the a disintegrin and metalloproteinase (ADAM) family, including ADAM10 and ADAM17, have been directly or indirectly associated with the constitutive and regulated α-secretase activities. Recent evidence in primary neuronal cultures indicates that ADAM10 may represent the genuine constitutive α-secretase. Mainly because α-secretase cleaves APP within the sequence of Aβ, the core component of the cerebral amyloid plaques in Alzheimer's disease, α-secretase activation is considered to be of therapeutic value. In this article, we will provide a historical perspective on the characterization of α-secretase and review the recent literature on the identification and biology of the current α-secretase candidates.
© 2011 The Authors. Journal of Neurochemistry © 2011 International Society for Neurochemistry.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22121879     DOI: 10.1111/j.1471-4159.2011.07477.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  35 in total

Review 1.  Abeta, oxidative stress in Alzheimer disease: evidence based on proteomics studies.

Authors:  Aaron M Swomley; Sarah Förster; Jierel T Keeney; Judy Triplett; Zhaoshu Zhang; Rukhsana Sultana; D Allan Butterfield
Journal:  Biochim Biophys Acta       Date:  2013-10-09

Review 2.  Omega-3 fatty acids, lipids, and apoE lipidation in Alzheimer's disease: a rationale for multi-nutrient dementia prevention.

Authors:  Marcus O W Grimm; Daniel M Michaelson; Tobias Hartmann
Journal:  J Lipid Res       Date:  2017-05-20       Impact factor: 5.922

3.  Protein levels of ADAM10, BACE1, and PSEN1 in platelets and leukocytes of Alzheimer's disease patients.

Authors:  Jessyka Maria de França Bram; Leda Leme Talib; Helena Passarelli Giroud Joaquim; Tamires Alves Sarno; Wagner Farid Gattaz; Orestes Vicente Forlenza
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-05-29       Impact factor: 5.270

Review 4.  More than cholesterol transporters: lipoprotein receptors in CNS function and neurodegeneration.

Authors:  Courtney Lane-Donovan; Gary T Philips; Joachim Herz
Journal:  Neuron       Date:  2014-08-20       Impact factor: 17.173

5.  Reduction of synaptojanin 1 accelerates Aβ clearance and attenuates cognitive deterioration in an Alzheimer mouse model.

Authors:  Li Zhu; Minghao Zhong; Jiaying Zhao; Hannah Rhee; Ina Caesar; Elysse M Knight; Laura Volpicelli-Daley; Victor Bustos; William Netzer; Lijuan Liu; Louise Lucast; Michelle E Ehrlich; Nikolaos K Robakis; Samuel E Gandy; Dongming Cai
Journal:  J Biol Chem       Date:  2013-09-19       Impact factor: 5.157

6.  Partial loss of endothelial nitric oxide leads to increased cerebrovascular beta amyloid.

Authors:  Susan A Austin; Zvonimir S Katusic
Journal:  J Cereb Blood Flow Metab       Date:  2019-01-07       Impact factor: 6.200

Review 7.  The Distinct Role of ADAM17 in APP Proteolysis and Microglial Activation Related to Alzheimer's Disease.

Authors:  Meng Qian; Xiaoqiang Shen; Huanhuan Wang
Journal:  Cell Mol Neurobiol       Date:  2015-06-29       Impact factor: 5.046

8.  Alzheimer disease: modeling an Aβ-centered biological network.

Authors:  D Campion; C Pottier; G Nicolas; K Le Guennec; A Rovelet-Lecrux
Journal:  Mol Psychiatry       Date:  2016-03-29       Impact factor: 15.992

Review 9.  The ADAMs family of proteases as targets for the treatment of cancer.

Authors:  Maeve Mullooly; Patricia M McGowan; John Crown; Michael J Duffy
Journal:  Cancer Biol Ther       Date:  2016-04-26       Impact factor: 4.742

Review 10.  Can BACE1 inhibition mitigate early axonal pathology in neurological diseases?

Authors:  Xiao-Xin Yan; Chao Ma; Wei-Ping Gai; Huaibin Cai; Xue-Gang Luo
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.